New Analyses from the IMPROVE-IT Study with VYTORIN® (ezetimibe and simvastatin)

Dateline City: KENILWORTH, N.J. Further Analyses on the Long-Term Safety and Efficacy of VYTORIN® from the IMPROVE-IT Study Presented at the European Society of Cardiology (ESC) Meeting KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD in the United States and Canada, today announced results from new analyses from the IMPROVE-IT study. “IMPROVE-IT presents us with the opportunity to look at cardiovascular outcomes data for patients treated with the combination of simvastatin and ezetimibe (VYTORIN) and allows us to look at the important aspect of long-term safety and efficacy under controlled conditions,” said Dr. Michael A. Blazing, Duke Department of Medicine. Language: English Contact: For MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Source Type: news

Related Links:

Publication date: Available online 18 August 2018Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Zeinab Mirzaei-KalarAbstractThe interaction of atorvastatin with calf thymus DNA (CT-DNA) was investigated in vitro under simulated physiological conditions by using absorption and emission spectroscopy, viscosity measurements, gel electrophoresis and molecular docking studies. Analysis of UV-Visible absorbance spectra indicates the formation of complex between atorvastatin and CT-DNA, and obtained binding constant (Kb = 8.2×104 L. mol-1) is comparable to groove binder drugs. Sligh...
Source: Journal of Pharmaceutical and Biomedical Analysis - Category: Drugs & Pharmacology Source Type: research
There are reports of melanoma (MM) after chronic exposure to a statin and 26% of the US population aged 40 and older are now estimated by the CDC to be chronically exposed to a statin, yet no statin describes MM as a risk in the Full Prescribing Information. We searched (01/01/2001 to 10/31/2017) a large Midwestern U.S. patient population, the Northwestern Medicine Electronic Data Warehouse, comprising a medical record data repository (> 5 million patients) that yielded data from adults (18-89 years) with at least 5 years of in-clinic follow-up.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Clinical Research: Epidemiology of Skin Diseases Source Type: research
Researchers from the University of Texas Southwestern found that people in their 40s with high 'bad' cholesterol levels of  100-to-159 mg/dL are up to 40 percent more at risk of death.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Clinical Cardiology,Volume 0, Issue ja, -Not available-.
Source: Clinical Cardiology - Category: Cardiology Authors: Source Type: research
Acute pancreatitis (AP) is the most common complication after endoscopic retrograde cholangiopancreatography (ERCP). Statins have been traditionally associated to an increased risk of AP, however, recent evidence suggests that statins may have a protective role against this disease.
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Tags: Progress Report Source Type: research
What risks do they pose to patient safety? Related items fromOnMedica Review launched into prescription drug dependency Online pharmacies undermine bid to curb antibiotic resistance Learning and growing together GPs defend practice on prescribing statins Non-adherence to medicine is as high as 50%
Source: OnMedica Blogs - Category: General Medicine Source Type: blogs
Neuropathology, EarlyView.
Source: Neuropathology - Category: Neurology Authors: Source Type: research
Authors: Li M, Liu F, Sang M, Sun X, Li L, Wang X Abstract The aim of the present study was to examine the effects of atorvastatinon p38 phosphorylation and cardiac remodeling after myocardial infarction in rats. A total of 43 rats were randomly divided into the control, sham operation, post-modeling medication (medication) and post-modeling non-medication (non-medication) groups. The control group did not receive any treatment. Anterior descending arteries of the rats in the medication and non-medication groups were ligated, and threading at the anterior descending arteries was conducted for the rats in the sham o...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Authors: Jia L, Wang L, Liu W, Qian G, Jiang X, Zhang Z Abstract The present study intended to investigate the effect of fluvastatin on cardiomyocyte apoptosis after myocardial infarction in rats. Eighty myocardial infarction rat models were established and randomly divided into 4 groups (n=20): experimental group (n=20) was given fluvastatin treatment; sham operation group (n=20) and normal control group (n=20) were given saline. The dose of fluvastatin was 20 mg/(kg·d), and irrigation gavage was given for 1 week. Western blot analysis and reverse transcription-quantitative PCR (RT-qPCR) were used to detect...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Authors: Garnacho-Montero J, Barrero-García I, Gómez-Prieto MG, Martín-Loeches I Abstract INTRODUCTION: Despite advances in modern medicine, severe community-acquired pneumonia (CAP) continues to be a potentially deadly disease. Mortality rate reaches up to the 50% in patients requiring admission to the Intensive Care Unit (ICU) when developing septic shock. Areas covered: We aim to describe the optimal management of severe CAP including antibiotic therapy, future antimicrobial options, and non-antibiotic (so-called adjunctive) therapies. A literature search was performed to identify all clinic...
Source: Expert Review of Anti-Infective Therapy - Category: Infectious Diseases Tags: Expert Rev Anti Infect Ther Source Type: research
More News: Cardiology | Cardiovascular | Heart | Merck | Pharmaceuticals | Simvastatin | Statin Therapy | Study | Vytorin | Zetia | Zocor